BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35833952)

  • 1. Fracture Risk and Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers.
    Holloway-Kew KL; Betson AG; Anderson KB; Sepetavc F; Gaston J; Kotowicz MA; Liao WH; Henneberg M; Pasco JA
    Calcif Tissue Int; 2022 Oct; 111(4):396-408. PubMed ID: 35833952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between bone measures and use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers.
    Holloway-Kew KL; Betson AG; Anderson KB; Gaston J; Kotowicz MA; Liao WH; Henneberg M; Pasco JA
    Arch Osteoporos; 2021 Sep; 16(1):137. PubMed ID: 34536130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.
    Zhang P; Zhu L; Cai J; Lei F; Qin JJ; Xie J; Liu YM; Zhao YC; Huang X; Lin L; Xia M; Chen MM; Cheng X; Zhang X; Guo D; Peng Y; Ji YX; Chen J; She ZG; Wang Y; Xu Q; Tan R; Wang H; Lin J; Luo P; Fu S; Cai H; Ye P; Xiao B; Mao W; Liu L; Yan Y; Liu M; Chen M; Zhang XJ; Wang X; Touyz RM; Xia J; Zhang BH; Huang X; Yuan Y; Loomba R; Liu PP; Li H
    Circ Res; 2020 Jun; 126(12):1671-1681. PubMed ID: 32302265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renin-angiotensin system inhibitors and risk of fractures: a prospective cohort study and meta-analysis of published observational cohort studies.
    Kunutsor SK; Blom AW; Whitehouse MR; Kehoe PG; Laukkanen JA
    Eur J Epidemiol; 2017 Nov; 32(11):947-959. PubMed ID: 28752198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of Osteoporotic Fractures With Angiotensin II Receptor Blockers Versus Angiotensin-Converting Enzyme Inhibitors in Hypertensive Community-Dwelling Elderly.
    Butt DA; Mamdani M; Gomes T; Lix L; Lu H; Tu K;
    J Bone Miner Res; 2014 Nov; 29(11):2483-8. PubMed ID: 24806397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality.
    Fosbøl EL; Butt JH; Østergaard L; Andersson C; Selmer C; Kragholm K; Schou M; Phelps M; Gislason GH; Gerds TA; Torp-Pedersen C; Køber L
    JAMA; 2020 Jul; 324(2):168-177. PubMed ID: 32558877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The renin-angiotensin aldosterone system and osteoporosis: findings from the Women's Health Initiative.
    Carbone LD; Vasan S; Prentice RL; Harshfield G; Haring B; Cauley JA; Johnson KC
    Osteoporos Int; 2019 Oct; 30(10):2039-2056. PubMed ID: 31209511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of Mild Cognitive Impairment or Probable Dementia in New Users of Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors: A Secondary Analysis of Data From the Systolic Blood Pressure Intervention Trial (SPRINT).
    Cohen JB; Marcum ZA; Zhang C; Derington CG; Greene TH; Ghazi L; Herrick JS; King JB; Cheung AK; Bryan N; Supiano MA; Sonnen JA; Weintraub WS; Scharfstein D; Williamson J; Pajewski NM; Bress AP;
    JAMA Netw Open; 2022 Jul; 5(7):e2220680. PubMed ID: 35834254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ARB users exhibit a lower fracture incidence than ACE inhibitor users among older hypertensive men.
    Kwok T; Leung J; Barrett-Connor E;
    Age Ageing; 2017 Jan; 46(1):57-64. PubMed ID: 28181652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Causes and impact on survival of underuse of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in heart failure.
    Bertero E; Miceli R; Lorenzoni A; Balbi M; Ghigliotti G; Chiarella F; Brunelli C; Viazzi F; Pontremoli R; Canepa M; Ameri P
    Intern Emerg Med; 2019 Oct; 14(7):1083-1090. PubMed ID: 30835055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and prognosis of hypertensive patients hospitalised with COVID-19.
    Covino M; De Matteis G; Burzo ML; Santoro M; Fuorlo M; Sabia L; Sandroni C; Gasbarrini A; Franceschi F; Gambassi G;
    Intern Med J; 2020 Dec; 50(12):1483-1491. PubMed ID: 33022124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stopping renin-angiotensin system blockers after acute kidney injury and risk of adverse outcomes: parallel population-based cohort studies in English and Swedish routine care.
    Bidulka P; Fu EL; Leyrat C; Kalogirou F; McAllister KSL; Kingdon EJ; Mansfield KE; Iwagami M; Smeeth L; Clase CM; Bhaskaran K; van Diepen M; Carrero JJ; Nitsch D; Tomlinson LA
    BMC Med; 2020 Jul; 18(1):195. PubMed ID: 32723383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of renin-angiotensin system inhibitors use on mortality in severe COVID-19 patients with hypertension: a retrospective observational study.
    Zhong Y; Zhao L; Wu G; Hu C; Wu C; Xu M; Dong H; Zhang Q; Wang G; Yu B; Lv J; Wu C; Zhang S; Cao C; Shu L; Pan Y; Liu X; Wu F
    J Int Med Res; 2020 Dec; 48(12):300060520979151. PubMed ID: 33322988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers and hemorrhoids: A nationwide, population-based study.
    Hu WS; Lin CL
    Medicine (Baltimore); 2023 Jun; 102(22):e33875. PubMed ID: 37266638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers may relate to the survival and walking ability in geriatric patients with hip fractures: a 1-year follow-up study.
    Chu Q; Wang L; Chu Q
    BMC Musculoskelet Disord; 2023 Mar; 24(1):236. PubMed ID: 36978079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association between renin angiotensin aldosterone system blockers and future osteoporotic fractures in a hypertensive population - A population-based cohort study in Taiwan.
    Kao YT; Huang CY; Fang YA; Liu JC
    Int J Cardiol; 2020 Apr; 305():147-153. PubMed ID: 31955975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers associated with lower risk of COVID-19 in household contacts.
    Armstrong K; Soltoff A; Rieu-Werden M; Metlay J; Haas J
    PLoS One; 2021; 16(3):e0247548. PubMed ID: 33651840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low body mass index is a risk factor for hyperkalaemia associated with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers treatments.
    Hirai T; Yamaga R; Fujita A; Itoh T
    J Clin Pharm Ther; 2018 Dec; 43(6):829-835. PubMed ID: 29908131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan.
    Wu LS; Chang SH; Chang GJ; Liu JR; Chan YH; Lee HF; Wen MS; Chen WJ; Yeh YH; Kuo CT; See LC
    Cardiovasc Diabetol; 2016 Apr; 15():56. PubMed ID: 27039185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin receptor blockers (ARB) outperform angiotensin-converting enzyme (ACE) inhibitors on ischemic stroke prevention in patients with hypertension and diabetes - A real-world population study in Taiwan.
    Pai PY; Muo CH; Sung FC; Ho HC; Lee YT
    Int J Cardiol; 2016 Jul; 215():114-9. PubMed ID: 27111172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.